Shares in NicOx SA rose more than 44 percent Tuesday on news that its glaucoma drug BOL-303259-X, which is partnered with Bausch & Lomb Inc., met the primary endpoint in a Phase IIb trial and will progress to a global Phase III development program within a year.
Johnson & Johnson, in a sense, is going head to head with itself by pitting its investigational protease inhibitor, TMC435, which it in-licensed from Medivir AB, against telaprevir, the hepatitis C virus (HCV) drug it markets as Incivo in Europe, Latin America, India and several other regions, in a Phase III trial.
Shares in NicOx SA rose more than 44 percent Tuesday on news that its glaucoma drug BOL-303259-X, which is partnered with Bausch & Lomb Inc., met the primary endpoint in a Phase IIb trial and will progress to a global Phase III development program within a year.
InDex Pharmaceuticals AB is moving its lead drug candidate Kappaproct into a European Phase III trial in patients with chronic active ulcerative colitis who are unresponsive to other therapies.
The month of May could prove to be an important milestone in the evolution of drug regulation in Europe. Around then, Amsterdam Molecular Therapeutics (AMT) Holding NV expects to hear a final decision from the European Medicines Agency (EMA) on its dossier for gene therapy treatment Glybera (alipogene tiparvovec), which has traced a highly circuitous route through various European Union institutions over the past couple of years.
InDex Pharmaceuticals AB is moving its lead drug candidate Kappaproct into a European Phase III trial in patients with chronic active ulcerative colitis who are unresponsive to other therapies.
The month of May could prove to be an important milestone in the evolution of drug regulation in Europe. Around then, Amsterdam Molecular Therapeutics (AMT) Holding NV expects to hear a final decision from the European Medicines Agency (EMA) on its dossier for gene therapy treatment Glybera (alipogene tiparvovec), which has traced a highly circuitous route through various European Union institutions over the past couple of years.
Basic biomedical research in Ireland is facing a period of significant uncertainty, following the publication of a report setting out a new overarching strategy for research in the country, which calls for greater emphasis on research areas that will enhance Ireland's appeal as a pharmaceutical manufacturing location.
Shares in struggling German drug developer Paion AG soared by more than 30 percent Tuesday on news that its partner, Lundbeck A/S, was handing it a financial lifeline by agreeing to pay €20.1 million (US$27 million) to acquire all outstanding rights to its Phase III stroke drug desmoteplase.
